Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology

Summary

The primary aim of this exploratory mechanistic study is to investigate the effects of Empagliflozin and Linagliptin on alpha- and beta cell physiology in T2DM patients. This study aims to evaluate the effect of the DPP-IV inhibitor linagliptin (as compared to placebo) in addition to the SGLT-2 inhibitor empagliflozin on pancreatic alpha and beta cell function, as well as several markers of metabolic control.

Timeline

Start

2015-05

Primary completion

2015-12

Completion

2015-12

Drugs

Indications